Stoke Therapeutics

Stoke Therapeutics

  • Founded: 2014
  • Location: Bedford, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Dravet syndrome (ODD)
  • Drug types: GEN, NEU, OPH, PED
  • Lead product: STK-001
  • Product link:
  • Funding: $97.5M stock Nov 2020; $142M IPO Jun 2019; $90M B Oct 2018; $40M A Jan 2018

job board

Short description:

Antisense Oligonucleotide Medicines

Drug notes:

STK-002 Clin1 autosomal dominant optic atrophy; undisclosed RD SYNGAP1 syndrome; undisclosed RD Rett syndrome; undisclosed RD CNS condition

Long description:

Contact us to add description.


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy